高级检索
    应志涛, 黄玲. Polatuzumab Vedotin联合苯达莫司汀及利妥昔单抗（pola-BR）对比苯达莫司汀联合利妥昔单抗（BR）治疗复发/难治性DLBCL的疗效分析[J]. 循证医学, 2020, 20(2): 72-75. DOI: 10.12019/j.issn.1671-5144.2020.02.002
    引用本文: 应志涛, 黄玲. Polatuzumab Vedotin联合苯达莫司汀及利妥昔单抗（pola-BR）对比苯达莫司汀联合利妥昔单抗（BR）治疗复发/难治性DLBCL的疗效分析[J]. 循证医学, 2020, 20(2): 72-75. DOI: 10.12019/j.issn.1671-5144.2020.02.002
    shu
    YING Zhi-tao, HUANG Ling. The Efficacy of Polatuzumab Vedotin with Bendamustine and Rituximab （pola-BR） versus Bendamustine and Rituximab （BR） in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma[J]. Journal of Evidence-Based Medicine, 2020, 20(2): 72-75. DOI: 10.12019/j.issn.1671-5144.2020.02.002
    Citation: YING Zhi-tao, HUANG Ling. The Efficacy of Polatuzumab Vedotin with Bendamustine and Rituximab （pola-BR） versus Bendamustine and Rituximab （BR） in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma[J]. Journal of Evidence-Based Medicine, 2020, 20(2): 72-75. DOI: 10.12019/j.issn.1671-5144.2020.02.002
    shu

    Polatuzumab Vedotin联合苯达莫司汀及利妥昔单抗（pola-BR）对比苯达莫司汀联合利妥昔单抗（BR）治疗复发/难治性DLBCL的疗效分析

    The Efficacy of Polatuzumab Vedotin with Bendamustine and Rituximab （pola-BR） versus Bendamustine and Rituximab （BR） in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

      摘要
      • HTML全文
      • 参考文献(15)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回